Trials / Completed
CompletedNCT01119339
Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis
An Investigator-blind, Controlled Study to Assess the Efficacy of Six Distinct Combinations of LAS 41004 in Different Concentrations Compared to Placebo and to Active Control in a Psoriasis-Plaque-Test
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Almirall, S.A. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to intra-individually compare the dose-related efficacy of LAS41004 in a Psoriasis Plaque Test (PPT)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LAS 41004 | LAS 41004 dosage 1, once daily |
| DRUG | LAS 41004 | LAS 41004 dosage 2, once daily |
| DRUG | LAS 41004 | LAS 41004 dosage 3, once daily |
| DRUG | LAS 41004 | LAS 41004 dosage 4, once daily |
| DRUG | LAS 41004 | LAS 41004 , dosage 5, once daily |
| DRUG | LAS 41004 dosage 6 | LAS 41004, dosage 6, once daily |
| DRUG | Placebo | Placebo, once daily |
| DRUG | Reference | Reference, once daily |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2010-05-07
- Last updated
- 2015-05-29
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01119339. Inclusion in this directory is not an endorsement.